<DOC>
	<DOCNO>NCT01995487</DOCNO>
	<brief_summary>The BioNIR study aim show BioNIR ridaforolimus elute stent non-inferior Resolute zotarolimus-eluting stent primary clinical endpoint target lesion failure ( TLF ) 12 month ; non-inferior Resolute secondary endpoint angiographic in-stent late loss 13 month ; cost-effective .</brief_summary>
	<brief_title>Study BioNIR Drug Eluting Stent System Coronary Stenosis</brief_title>
	<detailed_description>The BioNIR prospective , multi-center , single-blind , two-arm , randomized clinical trial . The population consist subject undergo PCI angina ( stable unstable ) , silent ischemia , NSTEMI , recent STEMI . Complex lesion allow . There limit number lesion per vessel individual lesion length ; however , total plan stenting coronary tree exceed 100mm . Randomization stratify presence medically treat diabetes vs. medically treat diabetes , acute coronary syndrome ( ACS ) vs. non-ACS , site . Lesions plan treat must declare recorded time randomization . Planned stag procedure , necessary , must declare immediately post procedure . Clinical follow-up perform 30 day , 6 month , 1 , 2 , 3 , 4 , 5 year post randomization . 200 patient participate North American site consent planned angiographic follow-up 13 month enrollment , 100 patient consent undergo plan IVUS baseline 13 month follow randomization . The primary endpoint Target Lesion Failure ( TLF ) 12 month , define composite cardiac death , target vessel-related myocardial infarction , ischemia-driven target lesion revascularization . Clinical Secondary Endpoints evaluate 30 day , 6 month , 1 , 2 , 3 , 4 5 , except note : - Device , Lesion , Procedure Success time baseline procedure - TLF 30 day , 6 month , 2 , 3 , 4 5 year define composite cardiac death , target vessel-related MI , ischemia-driven TLR . - Major adverse cardiac event ( MACE ; composite rate cardiac death , MI ischemia-driven TLR ) - Target vessel failure ( TVF ; composite rate death , target vessel related MI ischemia-driven TVR ) - All-cause mortality - Cardiac death - Myocardial Infarction - Target Vessel Related MI - Ischemia-driven TLR - Ischemia-driven TVR - Stent Thrombosis ( ARC definite probable ) Angiographic Sub-Study Secondary Endpoint evaluate 13 month : • Angiographic in-stent in-segment late loss IVUS Sub-Study Secondary Endpoint evaluate 13 month : - In-stent percent neointimal hyperplasia - Stent mal-apposition A key component trial prospective assessment health care resource utilization , cost cost effectiveness . A separate cost effectiveness assessment plan describe data collection analysis . Sample Size Consideration : From recent US trial best class DES ( Xience V , Promus Element Resolute ) , 1-year TLF rate patient non-complex lesion undergo routine angiographic follow-up approximately 3.8 % . Using assumption more-comers ' design , 1-year event rate conservatively increase 50 % ( assume enrollment rate complex patients/lesions 50 % double standard event rate ) - thus 5.8 % . Therefore , one-sided 95 % upper bound confidence interval 3.3 % ( relative 57 % margin ) 1:1 randomization , enrol 1810 patient ( 905 per group ) provide 90 % power demonstrate non-inferiority . Assuming 95 % follow-up rate 1 year , approximately 1906 patient enrol ( 953 group ) .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<criteria>Patient indication PCI include angina/silent ischemia/NSTEMI/recent STEMI Nontarget vessel PCI allow prior randomization depend time interval certain condition Patient/legal guardian willing &amp; able provide inform write consent &amp; comply followup visit &amp; test schedule Target lesion ( ) must locate native coronary artery/bypass graft conduit w/visually estimate diameter ≥2.5mm ≤4.25mm . Complex lesion allow , include calcify , presence thrombus , CTO , bifurcation ( except per exclusion criterion # 30 ) , ostial RCA , tortuous , bare metal stent restenotic , protect leave main , saphenous vein graft STEMI within 24 hour init . time presentation first treat hospital , enzyme level ( either CKMB Troponin ) peak PCI within 24 hour precede baseline procedure Nontarget lesion PCI target vessel within 12 month baseline procedure History stent thrombosis Cardiogenic shock ( persistent hypotension [ systolic blood pressure &lt; 90mm/Hg MT 30 min ] require pressors/hemodynamic support , include IABP ) Subject intubate Known LVEF &lt; 30 % Relative/absolute contraindication DAPT 12 month ( include plan surgery delay , subject indicate chronic oral anticoagulant treatment ) Calculated creatinine clearance &lt; 30 mL/min per CockcroftGault equation ( &lt; 40mL/min subject participate angiographic followup substudy ) Hemoglobin &lt; 10g/dL Platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 White blood cell ( WBC ) count &lt; 3,000 cells/mm3 Clinically significant liver disease Active peptic ulcer/active bleeding site Bleeding site within prior 8 wks require active medical/surgical attention If femoral access plan , significant peripheral arterial disease precludes safe insertion 6F sheath History bleeding diathesis/coagulopathy/will refuse blood transfusion Cerebrovascular accident/transient ischemic attack within past 6 month , permanent neurologic defect attribute CVA Known allergy study stent component , BioNIR Resolute Known allergy protocolrequired concomitant medication : aspirin/DAPT ( clopidogrel , prasugrel , ticagrelor ) /heparin bivalirudin/iodinated contrast adequately premedicated Any comorbid condition may cause noncompliance protocol ( e.g . dementia , substance abuse ) /reduced life expectancy &lt; 24 month ( e.g . cancer , severe heart failure , severe lung disease ) Patient participating/plans participate another investigational drug/device clinical trial reach primary endpoint Pregnant/breastfeeding woman ( woman childbearing potential must negative pregnancy test within 1 wk treatment ) Women intend become pregnant within 12 month baseline procedure ( sexually active woman childbearing potential must agree use reliable method contraception time screen 12 month post baseline procedure ) Patient received/is wait list organ transplant Patient receiving/scheduled receive chemotherapy within 30 day before/any time baseline procedure Patient receive oral/intravenous immunosuppressive therapy know lifelimiting immunosuppressive/autoimmune disease ( e.g . HIV ) ; corticosteroid allow More 100mm length plan stenting entire coronary tree Unprotected leave main lesion ≥30 % , plan leave main intervention Ostial LAD/LCX lesion ( stenting diseased segment within 5mm unprotected leave main coronary artery ) Bifurcation lesion plan dual stent implantation Stenting lesion due DES restenosis Another lesion target/nontarget vessel ( include side branch ) present requires/has high probability require PCI within 12 month baseline procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>comer</keyword>
	<keyword>DES</keyword>
	<keyword>BioNIR</keyword>
	<keyword>ACS</keyword>
	<keyword>non ACS</keyword>
	<keyword>complex lesion</keyword>
</DOC>